VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Lui Franciosi of Franciosi Consulting Ltd. has been intrigued with the growing interest in the use of psychedelic drugs for treating depression, anxiety and addiction. He has been reviewing the scientific literature and the history of these drugs to better understand their merit. The most commonly mentioned drugs and promising alternatives for patients unresponsive to traditional treatments are ayahuasca, psilocybin, dimethyltryptamine (DMT), or lysergic acid diethylamide (LSD). These psychedelics appear to be well-tolerated with the most common adverse effects being transient anxiety, short-lived headaches, nausea and mild increases in heart rate and blood pressure. Overall, they seem to be effective in reducing many disease symptoms. However, the scientific consensus is that even though these substances demonstrate rapid, sustained and well tolerated therapeutic effects with single or even a few doses, there is still a need for large-scale, randomised controlled studies to elucidate their potential safety and use in clinical practice.

See the original post:
Franciosi Consulting Reviewing the Science and History of Psychedelic Drug Use for Treating Depression, Anxiety and Addiction